Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

CCR5 blockade: A therapeutic approach to uncouple CART-BCMA expansion from CART-mediated immune toxicities.

Blood (2025) 146 (Supplement 1): 5945.

https://doi.org/10.1182/blood-2025-5945

Published: 2025

Journal Articles

Single-day non-activated IL-18-armed CAR T cells with enhanced persistence and durable efficacy

Joseph Durgin, Shin Seo, Shadab Kazmi, Bakir Valentic, Chloe Leff, Xioling Jin, Feng Shen, Nandana Mukherjee, Ashwin Sannecy, Gabriela Plesa, Khatuna Gabunia, John Scholler, Saar Gill, Roddy O'Connor, Carl June, Saba Ghassemi

Blood (2025) 146 (Supplement 1): 4187.

https://doi.org/10.1182/blood-2025-4187

Published: 2025

Journal Articles

Glucose transporter 5 enhances CAR-T cell metabolic function and serial killing

Bakir Valentic, Andre Kelly, Feng Shen, John Scholler, Max Shestov, Nathaniel Snyder, Saba Ghassemi, Nicholas Jones, Saar Gill, Roddy O'Connor

Blood (2025) 146 (Supplement 1): 2351.

https://doi.org/10.1182/blood-2025-2351

Published: 2025

Journal Articles

Delayed neurotoxicity, enterocolitis, and BCMA-CART-associated immune-related adverse events (CirAE) are caused by CD4+ CAR T-cells

Blood (2025) 146 (Supplement 1): 804.

https://doi.org/10.1182/blood-2025-804

Published: 2025

Journal Articles

Metabolic conditioning for enhanced CAR T cell function

Blood (2025) 146 (Supplement 1): 4127.

https://doi.org/10.1182/blood-2025-4127

Published: 2025

Journal Articles

Disinhibition of T Cell Activation Via CD5 Knockout Is a Universal Strategy to Enhance Adoptive T Cell Immunotherapies

Ruchi P. Patel, Guido Ghilardi, Yunlin Zhang, Puneeth Guruprasad, Mathew G. Angelos, Raymone Pajarillo, Khatuna Gabunia, Chong Xu, Tatiana Blanchard, John Scholler, Patrizia Porazzi, Gerald Linette, Beatriz M. Carreno, Marco Ruella

Blood (2023) 142 (Supplement 1): 102.

https://doi.org/10.1182/blood-2023-186611

Published: 2023

Journal Articles

Interleukin-18 Secreting Autologous Anti-CD19 CAR T-Cells (huCART19-IL18) in Patients with Non-Hodgkin Lymphomas Relapsed or Refractory to Prior CAR T-Cell Therapy

Blood (2022) 140 (Supplement 1): 4612–4614.

https://doi.org/10.1182/blood-2022-162393

Published: 2022

Journal Articles

Gut Microbiota Tuning Promotes Tumor-Associated Antigen Cross Presentation and Enhances CAR T Antitumor Effects

Marco Ruella, Mireia Uribe-Herranz, Silvia Beghi, Kalpana Parvathaneni, Nektarios Kostopoulos, Guido Ghilardi, Kimberly Amelsberg, Yong Gu Gu Lee, Raymone Pajarillo, Noelle V Frey, Simon F Lacey, Khatuna Gabunia, John Scholler, Elise A Chong, Carl H June, David L. Porter, Stephen J. Schuster, Vijay Bhoj, Andrea Facciabene

Blood (2021) 138 (Supplement 1): 163.

https://doi.org/10.1182/blood-2021-151093

Published: 2021

Journal Articles

Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Blood (2017) 130 (Supplement 1): 1319.

https://doi.org/10.1182/blood.V130.Suppl_1.1319.1319

Published: 2017

Journal Articles

Oncolytic Adenovirus Expressing Cytokines Enhances Anti-Tumor Efficacy of Mesothelin-Redirected CAR-T Cells

Keisuke Watanabe, MD PhD, Sonia Guedan, PhD, John Scholler, Shannon McGettigan, Yangpin Luo, Siri Tähtinen, Suvi Parviainen, PhD, Riikka Havunen, Mikko Siurala, Akseli Hemminki, MD PhD, Carl H June, MD

Blood (2016) 128 (22): 3360.

https://doi.org/10.1182/blood.V128.22.3360.3360

Published: 2016

Journal Articles

Cars in Leukemia: Relapse with Antigen-Negative Leukemia Originating from a Single B Cell Expressing the Leukemia-Targeting CAR

Blood (2016) 128 (22): 281.

https://doi.org/10.1182/blood.V128.22.281.281

Published: 2016

Journal Articles

Minimally Ex Vivo Manipulated Gene-Modified T Cells Display Enhanced Tumor Control

Saba Ghassemi, PhD, Patel Prachi, John Scholler, Selene Nunez-Cruz, PhD, David M. Barrett, MD PhD, Felipe Bedoya, PhD, Joseph A. Fraietta, PhD, Simon Francis Lacey, PhD BS, Bruce L Levine, PhD, Stephen A. Grupp, MD PhD, Carl H June, MD, Michael C. Milone, MD PhD, J. Joseph Melenhorst, PhD

Blood (2016) 128 (22): 4549.

https://doi.org/10.1182/blood.V128.22.4549.4549

Published: 2016

Journal Articles

Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Blood (2016) 128 (22): 217.

https://doi.org/10.1182/blood.V128.22.217.217

Published: 2016

Journal Articles

Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL

Blood (2015) 126 (23): 683.

https://doi.org/10.1182/blood.V126.23.683.683

Published: 2015

Journal Articles

A Novel Small Animal Model to Test on-Target Off-Tumor Cytoxicity of Adoptive Immune Therapies

Mauro Castellarin, PhD, Joseph A. Fraietta, PhD, Jihyun Lee, PhD, John Scholler, Yangbing Zhao, PhD MD, Carl H. June, MD

Blood (2015) 126 (23): 5432.

https://doi.org/10.1182/blood.V126.23.5432.5432

Published: 2015

Journal Articles

Combination of Anti-CD123 and Anti-CD19 Chimeric Antigen Receptor T Cells for the Treatment and Prevention of Antigen-Loss Relapses Occurring after CD19-Targeted Immunotherapies

Marco Ruella, MD, David M. Barrett, MD PhD, Saad S Kenderian, MD, Olga Shestova, PhD, Ted J. Hofmann, PhD, John Scholler, Simon F. Lacey, PhD BSc, J. Joseph Melenhorst, PhD, Farzana Nazimuddin, Jessica Perazzelli, PhD, David A Christian, PhD, Christopher A Hunter, PhD, David L Porter, MD, Carl H. June, MD, Stephan A. Grupp, MD PhD, Saar I Gill, MBBS, PhD

Blood (2015) 126 (23): 2523.

https://doi.org/10.1182/blood.V126.23.2523.2523

Published: 2015

Journal Articles

Novel Chimeric Antigen Receptor T Cells for the Treatment of CD19-Negative Relapses Occurring after CD19-Targeted Immunotherapies

Marco Ruella, MD, David Barrett, MD PhD, Saad S. Kenderian, MD, Olga Shestova, PhD, Ted J. Hofmann, PhD, John Scholler, Simon F. Lacey, PhD BSc, Jan J Melenhorst, PhD, Farzana Nazimuddin, MS, Michael Kalos, PhD, David L. Porter, MD, Carl H. June, MD, Stephan A. Grupp, MD PhD, Saar I. Gill, MD PhD

Blood (2014) 124 (21): 966.

https://doi.org/10.1182/blood.V124.21.966.966

Published: 2014

Journal Articles

Novel Chimeric Antigen Receptor T Cells for the Treatment of Hodgkin Lymphoma

Marco Ruella, MD, Saad S Kenderian, MD, Olga Shestova, PhD, Taylor Chen, John Scholler, Mariusz A. Wasik, MD, Carl H. June, MD, Saar I. Gill, MD PhD

Blood (2014) 124 (21): 806.

https://doi.org/10.1182/blood.V124.21.806.806

Published: 2014

Journal Articles

Signaling Domain of Chimeric Antigen Receptors Can Reprogram T Cells

Omkar Uday Kawalekar, MS, BS, Roddy O'Connor, PhD, Sonia Guedan, PhD, Joseph Fraietta, PhD, Avery D. Posey, PhD, John Scholler, Michael C Milone, MD PhD, Carl H. June, MD

Blood (2014) 124 (21): 551.

https://doi.org/10.1182/blood.V124.21.551.551

Published: 2014

Journal Articles

ICOS-based chimeric antigen receptors program bipolar T H 17/T H 1 cells

Sonia Guedan, Xi Chen, Aviv Madar, Carmine Carpenito, Shannon E. McGettigan, Matthew J. Frigault, Jihyun Lee, Avery D. Posey, Jr, John Scholler, Nathalie Scholler, Richard Bonneau, Carl H. June

Blood (2014) 124 (7): 1070–1080.

https://doi.org/10.1182/blood-2013-10-535245

Published: 2014

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CCR5 blockade: A therapeutic approach to uncouple CART-BCMA expansion from CART-mediated immune toxicities.

Single-day non-activated IL-18-armed CAR T cells with enhanced persistence and durable efficacy

Glucose transporter 5 enhances CAR-T cell metabolic function and serial killing

Delayed neurotoxicity, enterocolitis, and BCMA-CART-associated immune-related adverse events (CirAE) are caused by CD4+ CAR T-cells

Metabolic conditioning for enhanced CAR T cell function

Disinhibition of T Cell Activation Via CD5 Knockout Is a Universal Strategy to Enhance Adoptive T Cell Immunotherapies

Interleukin-18 Secreting Autologous Anti-CD19 CAR T-Cells (huCART19-IL18) in Patients with Non-Hodgkin Lymphomas Relapsed or Refractory to Prior CAR T-Cell Therapy

Gut Microbiota Tuning Promotes Tumor-Associated Antigen Cross Presentation and Enhances CAR T Antitumor Effects

Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Oncolytic Adenovirus Expressing Cytokines Enhances Anti-Tumor Efficacy of Mesothelin-Redirected CAR-T Cells

Cars in Leukemia: Relapse with Antigen-Negative Leukemia Originating from a Single B Cell Expressing the Leukemia-Targeting CAR

Minimally Ex Vivo Manipulated Gene-Modified T Cells Display Enhanced Tumor Control

Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL

A Novel Small Animal Model to Test on-Target Off-Tumor Cytoxicity of Adoptive Immune Therapies

Combination of Anti-CD123 and Anti-CD19 Chimeric Antigen Receptor T Cells for the Treatment and Prevention of Antigen-Loss Relapses Occurring after CD19-Targeted Immunotherapies

Novel Chimeric Antigen Receptor T Cells for the Treatment of CD19-Negative Relapses Occurring after CD19-Targeted Immunotherapies

Novel Chimeric Antigen Receptor T Cells for the Treatment of Hodgkin Lymphoma

Signaling Domain of Chimeric Antigen Receptors Can Reprogram T Cells

ICOS-based chimeric antigen receptors program bipolar T H 17/T H 1 cells

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only